A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size.
- Authors
- Lötsch, Jörn; Prüss, Harald; Veh, Rüdiger W; Doehring, Alexandra
- Year
- 2010
- Journal
- Pharmacogenetics and genomics
- PMID
- 20220551
- DOI
- 10.1097/FPC.0b013e3283386bda
AIM: KCNJ6 coding for potassium inwardly rectifying channels (Kir3.2, GIRK2) is important for opioid receptor transmission. The KCNJ6 rs2070995 AA genotype has been associated with increased opioid analgesic requirements in Japanese. We analyzed its consequences for other opioid effects. METHODS: Genotyping was done in 85 methadone-substituted former heroin addicts, 352 opioid-treated chronic pain patients, and in 51 healthy volunteers where miotic effects of levomethadone had been measured. Expression of Kir3.2 in the Edinger-Westphal nucleus of rat brains was analyzed by means of immunohistochemistry. RESULTS: Average daily methadone substitution doses during the first therapy year were larger in the AA genotype (n=4, 119.7+/-49.6 mg/day) than in other rs2070995 genotypes (77.5+/-26.2 mg/day, P=0.003) whereas AA carriers lacked opioid withdrawal symptoms. A similar tendency toward less opioid effectiveness was observed toward higher opioid dosing demands for analgesia in the AA genotype (n=17, opioid dose 2.03+/-0.45 log mg oral morphine equivalents per day, controls: 1.81+/-0.52 log mg oral morphine equivalents/day, P=0.093). In contrast, no pharmacogenetic effects were observed on miotic opioid effects. This could be traced back to the absence of Kir3.2 from the Edinger-Westphal nucleus in rat brains, a key cerebral structure governing pupil constriction. CONCLUSION: The association of the KCNJ6 rs2070995 AA genotype with increased opioid requirements extends from analgesia to opiate substitution therapy. Opioid induced miosis is exempted for molecular histological reasons.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Preliminary Prospective Study on the Association of Polymorphisms in <i>BDNF</i>, <i>ARRB2</i> and <i>KCNJ6</i> and Response to Fentanyl for Pain Management in Advanced Cancer. | Prenzler J et al. | — | 2025 | → |
| Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life. | Ozberk D et al. | — | 2022 | → |
| Neuronal G protein-gated K<sup>+</sup> channels. | Luo H et al. | — | 2022 | → |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | — | 2022 | → |
| Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study. | Tanaka R et al. | — | 2021 | → |
| Kir Channel Molecular Physiology, Pharmacology, and Therapeutic Implications. | Cui M et al. | — | 2021 | → |
| Potassium Channels and Their Potential Roles in Substance Use Disorders. | McCoy MT et al. | — | 2021 | → |
| Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system. | Jeremic D et al. | — | 2021 | → |
| Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study. | Margarit C et al. | — | 2019 | → |
| Pharmacogenetics of Methadone Response. | Fonseca F et al. | — | 2018 | → |
| Pharmacogenetics of Opioid Use Disorder Treatment. | Crist RC et al. | — | 2018 | → |
| A KCNJ6 gene polymorphism modulates theta oscillations during reward processing. | Kamarajan C et al. | — | 2017 | → |
| Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. | Matic M et al. | — | 2017 | → |
| Dual activation of neuronal G protein-gated inwardly rectifying potassium (GIRK) channels by cholesterol and alcohol. | Glaaser IW et al. | — | 2017 | → |
| Genetic correlates of the development of theta event related oscillations in adolescents and young adults. | Chorlian DB et al. | — | 2017 | → |
| Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl. | Lloyd RA et al. | — | 2017 | → |
| Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. | Elens L et al. | — | 2016 | → |
| Molecular Pharmacology of δ-Opioid Receptors. | Gendron L et al. | — | 2016 | → |
| Opioid treatment failure in cancer patients: the role of clinical and genetic factors. | Oosten AW et al. | — | 2016 | → |
| The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. | Christoffersen DJ et al. | — | 2016 | → |
| Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction. | Mayfield J et al. | — | 2015 | → |
| G protein-gated inwardly rectifying potassium channel subunits 1 and 2 are down-regulated in rat dorsal root ganglion neurons and spinal cord after peripheral axotomy. | Lyu C et al. | — | 2015 | → |
| Association between KCNJ6 (GIRK2) gene polymorphism rs2835859 and post-operative analgesia, pain sensitivity, and nicotine dependence. | Nishizawa D et al. | — | 2014 | → |
| Association of μ-opioid receptor gene (OPRM1) haplotypes with postoperative nausea and vomiting. | Sugino S et al. | — | 2014 | → |
| Kir3 channel signaling complexes: focus on opioid receptor signaling. | Nagi K et al. | — | 2014 | → |
| New insights into the therapeutic potential of Girk channels. | Luján R et al. | — | 2014 | → |
| Pharmacogenetics of addiction therapy. | Nielsen DA et al. | — | 2014 | → |
| Pharmacogenomics of methadone maintenance treatment. | Somogyi AA et al. | — | 2014 | → |
| Associations between KCNJ6 (GIRK2) gene polymorphisms and pain-related phenotypes. | Bruehl S et al. | — | 2013 | → |
| Genetics and alcoholism. | Edenberg HJ et al. | — | 2013 | → |
| Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia. | Lötsch J et al. | — | 2013 | → |
| Pharmacogenetics of chronic pain and its treatment. | Světlík S et al. | — | 2013 | → |
| Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. | Hajj A et al. | — | 2013 | → |
| Pharmacokinetics of non-intravenous formulations of fentanyl. | Lötsch J et al. | — | 2013 | → |
| ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. | Barratt DT et al. | — | 2012 | → |
| Endogenous opiates and behavior: 2011. | Bodnar RJ | — | 2012 | → |
| Family-based genome-wide association study of frontal θ oscillations identifies potassium channel gene KCNJ6. | Kang SJ et al. | — | 2012 | → |
| Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. | Levran O et al. | — | 2012 | → |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | — | 2012 | → |
| Effect sizes in experimental pain produced by gender, genetic variants and sensitization procedures. | Doehring A et al. | — | 2011 | → |
| Genetic variability of pain perception and treatment--clinical pharmacological implications. | Lötsch J | — | 2011 | → |